Gut microbiota-mediated IL-22 alleviates metabolic inflammation.
Disease
Gut microbiota
IL-22
Inflammation
Metabolism
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
28
08
2023
revised:
25
10
2023
accepted:
29
10
2023
medline:
20
11
2023
pubmed:
5
11
2023
entrez:
3
11
2023
Statut:
ppublish
Résumé
Low-grade chronic inflammation, also known as metabolic inflammation, promotes the development of metabolic diseases. Increasing evidence suggests that changes in gut microbes and metabolites disrupt the integrity of the gut barrier and exert significant effects on the metabolism of various tissues, including the liver and adipose tissue, thereby contributing to metabolic inflammation. We observed that IL-22 is a key signaling molecule that serves as a bridge between intestinal microbes and the host, effectively alleviating metabolic inflammation by modulating the host immunomodulatory network. Here, we focused on elucidating the underlying mechanisms by which the gut microbiota and their metabolites reduce inflammation via IL-22, highlighting the favorable impact of IL-22 on metabolic inflammation. Furthermore, we discuss the potential of IL-22 as a therapeutic target for the management of metabolic inflammation and related diseases.
Identifiants
pubmed: 37922980
pii: S0024-3205(23)00864-0
doi: 10.1016/j.lfs.2023.122229
pii:
doi:
Substances chimiques
Interleukins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
122229Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.